Acute Major Eye Infections without CC/MCC DRG Reimbursement

DRG 122 encompasses inpatient treatment for acute major eye infections without Major Complication or Comorbidity or Complication or Comorbidity, reflecting a specific clinical population with significant resource needs. Correct classification matters for inpatient reimbursement because Medicare payment is prospectively determined by the Diagnosis-Related Group assignment tied to documented diagnoses and procedures.

DRG 122 Overview

DRG 122 covers hospital admissions for acute major eye infections that do not have a Major Complication or Comorbidity and do not have a Complication or Comorbidity. These cases typically include severe intraocular or periocular infections requiring inpatient medical or surgical management. This Diagnosis-Related Group is important for Medicare payment because it groups clinically similar resource use to determine a single prospective reimbursement amount. Hospitals and coders must accurately capture principal and secondary diagnoses to ensure correct assignment to this DRG.

Early acute intervention trials focusing on topical and local antimicrobial strategies for severe bacterial or fungal keratitis and endophthalmitis: these studies enroll hospitalized adults presenting with vision-threatening acute eye infections to evaluate timing, dosing regimens, and delivery methods (e.g., fortified topical antibiotic drops, intravitreal injections, or local antimicrobial delivery systems). The objective is to determine whether specific early intervention protocols reduce need for surgical procedures, shorten hospital length of stay, and preserve visual acuity; results are directly relevant to inpatient care pathways, resource use, and short-term reimbursement for intensive treatments.
Comparative effectiveness research comparing medical versus surgical management pathways for complicated acute eye infections: trials or observational comparative studies examine subpopulations such as immunocompromised patients, diabetics, or those with prior ocular surgery to compare outcomes of aggressive medical therapy alone versus combined procedures (e.g., debridement, vitrectomy), measuring clinical outcomes, complication rates, and downstream resource utilization. This research informs clinical decision-making about when operative intervention is warranted, impacts coding and DRG assignment decisions, and helps payers and hospitals predict costs and potential readmissions.
Post-discharge outcomes and care coordination studies assessing functional recovery, vision-related quality of life, and readmission risk after inpatient treatment for major eye infections: prospective cohorts or pragmatic trials test different discharge strategies, such as structured outpatient follow-up, home infusion services, or teleophthalmology check-ins, in patients discharged after acute infection treatment. These studies focus on preventing relapse, reducing emergency returns, and optimizing outpatient antimicrobial adherence—issues that affect long-term outcomes, ambulatory care costs, and bundled payment models relevant to payers and providers managing DRG 122 patients.

Early acute intervention trials focusing on topical and local antimicrobial strategies for severe bacterial or fungal keratitis and endophthalmitis: these studies enroll hospitalized adults presenting with vision-threatening acute eye infections to evaluate timing, dosing regimens, and delivery methods (e.g., fortified topical antibiotic drops, intravitreal injections, or local antimicrobial delivery systems). The objective is to determine whether specific early intervention protocols reduce need for surgical procedures, shorten hospital length of stay, and preserve visual acuity; results are directly relevant to inpatient care pathways, resource use, and short-term reimbursement for intensive treatments.
Comparative effectiveness research comparing medical versus surgical management pathways for complicated acute eye infections: trials or observational comparative studies examine subpopulations such as immunocompromised patients, diabetics, or those with prior ocular surgery to compare outcomes of aggressive medical therapy alone versus combined procedures (e.g., debridement, vitrectomy), measuring clinical outcomes, complication rates, and downstream resource utilization. This research informs clinical decision-making about when operative intervention is warranted, impacts coding and DRG assignment decisions, and helps payers and hospitals predict costs and potential readmissions.
Post-discharge outcomes and care coordination studies assessing functional recovery, vision-related quality of life, and readmission risk after inpatient treatment for major eye infections: prospective cohorts or pragmatic trials test different discharge strategies, such as structured outpatient follow-up, home infusion services, or teleophthalmology check-ins, in patients discharged after acute infection treatment. These studies focus on preventing relapse, reducing emergency returns, and optimizing outpatient antimicrobial adherence—issues that affect long-term outcomes, ambulatory care costs, and bundled payment models relevant to payers and providers managing DRG 122 patients.

OpenPayer

Summary & Overview

Acute Major Eye Infections without CC/MCC: Inpatient Reimbursement Overview

DRG 122 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes